Bonnie Gillis

Articles

Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer

October 3rd 2013

Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA-1 trial.

Novel ALK Inhibitor Shows Promise Against Brain Metastasis in NSCLC

September 30th 2013

The first-in-human phase I/II dose-finding study of a novel ALK/EGFR inhibitor called AP26113 demonstrated promising results in both crizotinib-resistant and crizotinib-naïve patients with non-small cell lung cancer.

BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus

September 30th 2013

Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels.

PD-L1 Inhibitor Delivers Rapid, Durable Responses in Advanced NSCLC

September 29th 2013

A phase I study has shown remarkable and durable responses with the engineered monoclonal antibody MPDL3280A in metastatic non-small cell lung cancer, including tumors with squamous and adenocarcinoma histology.

T-DM1 Extends PFS in Heavily Pretreated Advanced Breast Cancer

September 29th 2013

T-DM1 extended progression-free survival compared with "physician's choice of treatment" in women with metastatic HER2-positive breast cancer.

Surveillance Following Orchiectomy Most Costly Option for Stage I Testicular Seminoma

May 2nd 2013

A cost analysis found that para-aortic radiotherapy, dogleg radiotherapy, and 1 cycle of carboplatin are cost-effective strategies for the management of stage I testicular seminoma post-orchiectomy compared with surveillance.

Use of Sipuleucel-T Refined

April 30th 2013

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.

Adding Vorinostat to Standard Chemotherapy Reduced the Incidence of Acute GVHD

March 7th 2013

Vorinostat added to standard chemotherapy before, during, and after hematopoietic stem-cell transplantation reduced the cumulative incidence of graft-versus-host disease.

Dasatinib Combination Fails to Improve Outcomes in mCRPC

February 15th 2013

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

Abiraterone Continues to Show Survival Benefit in Updated Interim Analysis

February 15th 2013

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

Concomitant Corticosteroid Use Dilutes Benefit of Enzalutamide in mCPRC

February 15th 2013

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

Study Shows Eribulin Not Superior to Capecitabine in Previously Treated Metastatic Breast Cancer

December 7th 2012

Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.

HDAC Inhibition Appears to Sensitize Triple-Negative Breast Cancer Cells to Certain Treatments

December 6th 2012

Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

December 5th 2012

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer

December 5th 2012

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Researchers Seek Optimal Dose of Cabozantinib in mCRPC

December 5th 2012

Single-agent cabozantinib has shown promising activity in early-stage trials involving heavily pretreated patients with metastatic castration-resistant prostate cancer. Researchers are now attempting to find the optimal dose of the drug in this patient population.

EGFR Mutation Status Might Predict Sorafenib Benefit in NSCLC

November 30th 2012

Results of the phase III MISSION trial showed that third- or fourth-line treatment with sorafenib did not improve overall survival in patients with advanced non–small cell lung cancer.

Temsirolimus/Bevacizumab Not Superior to Standard Treatment With Interferon/Bevacizumab in mRCC

November 29th 2012

The combination of temsirolimus plus bevacizumab was not superior to interferon plus bevacizumab as first-line therapy for patients with clear cell metastatic renal cell carcinoma.

Enzalutamide Delays First Skeletal-Related Event, Improves Pain and QOL in Patients With Metastatic Prostate Cancer

November 27th 2012

Enzalutamide significantly delayed the time to first SRE and significantly improved pain and QOL compared with placebo in men with mCRPC who had received prior docetaxel.

Bevacizumab PFS Benefit Extends Across Cohorts in AURELIA Trial

November 20th 2012

An exploratory analysis of the phase III AURELIA trial demonstrated that adding bevacizumab (Avastin) to chemotherapy in patients with platinum-resistant ovarian cancer benefited patients across treatment cohorts.

NEXT PAGE
PREVIOUS PAGE